SCHEMBL5135938

SCHEMBL5135938

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(F)cc1F)CC1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
P2RX7 Q99572 2/20 0.36
CCR4 P51679 2/20 0.36
HDAC1 Q13547 1/20 0.36
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
TSHR P16473 2/20 0.34
CRHR1 P34998 4/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP3A4 P08684 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HTR2A P28223 2/20 0.34
DRD1 P21728 1/20 0.33
DRD4 P21917 1/20 0.33
DRD5 P21918 1/20 0.33
HTR2C P28335 1/20 0.33
DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136891 0.94 C5AR1 (0.41) C5AR1P2RX7CCR4HDAC1BCHE
SCHEMBL651851 0.92 C5AR1 (0.40) C5AR1P2RX7CCR4HDAC1BCHE
SCHEMBL5136106 0.91 C5AR1 (0.41) C5AR1P2RX7CCR4HDAC1BCHE
SCHEMBL646859 0.91 C5AR1 (0.39) C5AR1CCR4HDAC1BCHEACHE
SCHEMBL5137114 0.88 C5AR1 (0.43) C5AR1P2RX7HDAC1BCHETSHR
SCHEMBL650740 0.87 C5AR1 (0.39) C5AR1P2RX7CCR4HDAC1BCHE
SCHEMBL650474 0.87 C5AR1 (0.42) C5AR1P2RX7CCR4HDAC1BCHE
SCHEMBL649769 0.87 C5AR1 (0.40) C5AR1CCR4HDAC1BCHEACHE
SCHEMBL651501 0.87 C5AR1 (0.44) C5AR1HDAC1TSHRCRHR1KDM4E
SCHEMBL5136912 0.86 C5AR1 (0.42) C5AR1CCR4HDAC1BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed